Doctors have for the first time in the United States tested a powerful gene-editing technique in people with cancer.
Thanks to the complete sequencing of the human genome, scientists are now able to understand the functioning of our body and what could cause a particular disease. According to the OECD, by 2030, biotechnology will have a significant impact on the global economy: biotech will account for 80% of pharmaceutical products, 50% of agricultural products, 35% of chemical and industrial products, ultimately contributing to a total of 2.7% of global GDP.
In healthcare, new biotechnology drug sales already exceed USD 350 billion and in the top ten best-selling drugs in the world as many as eight derived from biotechnology companies.
We are living in the era of biotechnology!
Doctors have for the first time in the United States tested a powerful gene-editing technique in people with cancer.
In the earnings call yesterday after the close, Nektar Therapeutics (NASDAQ:NKTR) President & CEO Howard Robin mentioned a "softening in response rates" in the Phase 1/2 PIVOT-02 study evaluating NKTR-214 (bempegaldesleukin)
The FDA approves Incyte's Jakafi (ruxolitinib) for the treatment of steroid-refractory acute graft-versus-host disease (GvHD)
Copyright © 2024 | J. LAMARCK S.P.A. Powered by Moving